Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
Kyu-Hyoung Lim, Ho-Il Yoon, Young Ae Kang, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jae Ho Lee, Choon-Taek Lee, Jong Seok Lee
Korean J Intern Med. 2010;25(1):86-92.   Published online 2010 Feb 26     DOI: https://doi.org/10.3904/kjim.2010.25.1.86
Citations to this article as recorded by Crossref logo
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
Marta Francesca Di Pasquale, Giovanni Sotgiu, Andrea Gramegna, Dejan Radovanovic, Silvia Terraneo, Luis F Reyes, Jan Rupp, Juan González del Castillo, Francesco Blasi, Stefano Aliberti, Marcos I Restrepo, Patricia Karina Aruj, Silvia Attorri, Enrique Bari
Clinical Infectious Diseases.2019; 68(9): 1482.     CrossRef
Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma
Wei Ping Liu, Xiao Pei Wang, Wen Zheng, Yan Xie, Mei Feng Tu, Ning Jing Lin, Ling Yan Ping, Zhi Tao Ying, Chen Zhang, Li Juan Deng, Ning Ding, Xiao Gan Wang, Yu Qin Song, Jun Zhu
Annals of Hematology.2018; 97(1): 133.     CrossRef
Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival
Kimberly Keefer, Regis Bender, Jason Liao, Jeffrey Sivik, Andry Van de Louw
Annals of Hematology.2018; 97(12): 2373.     CrossRef
Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients
Mingxiao Lang, Jingwei Yu, Xianhuo Wang, Zheng Song, Lanfang Li, Lihua Qiu, Huilai Zhang
Hematological Oncology.2018; 36(5): 779.     CrossRef
Drug-Induced Interstitial Lung Disease: A Systematic Review
Sarah Skeoch, Nicholas Weatherley, Andrew Swift, Alexander Oldroyd, Christopher Johns, Conal Hayton, Alessandro Giollo, James Wild, John Waterton, Maya Buch, Kim Linton, Ian Bruce, Colm Leonard, Stephen Bianchi, Nazia Chaudhuri
Journal of Clinical Medicine.2018; 7(10): 356.     CrossRef
Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors
Ioannis Kyriakidis, Athanasios Tragiannidis, Ilse Zündorf, Andreas H. Groll
Mycoses.2017; 60(8): 493.     CrossRef
TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+T-cell lymphoma
Wenyu Shi, Suraj Konnath George, Bhawana George, Choladda V. Curry, Albina Murzabdillaeva, Serhan Alkan, Hesham M. Amin
Molecular Oncology.2017; 11(9): 1189.     CrossRef
Doxorubicin Induces Inflammatory Modulation and Metabolic Dysregulation in Diabetic Skeletal Muscle
Rashmi Supriya, Bjorn T. Tam, Xiao M. Pei, Christopher W. Lai, Lawrence W. Chan, Benjamin Y. Yung, Parco M. Siu
Frontiers in Physiology.2016;[Epub]     CrossRef
Pneumocystispneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy
Se Yoon Park, Mi Young Kim, Won Jin Choi, Dok Hyun Yoon, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Cheolwon Suh, Jun Hee Woo, Sung-Han Kim
Medical Mycology.2016; : myw095.     CrossRef
Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab
Giselle Salmasi, Michael Li, Vithika Sivabalasundaram, Tony Panzarella, Richard Tsang, Vishal Kukreti, Michael Crump, John Kuruvilla
Leukemia & Lymphoma.2015; 56(6): 1659.     CrossRef
Fatal rituximab-associated lung injury syndrome in a patient treated with rituximab for recurrence of post-transplant nephrotic syndrome
Ryszard Grenda, Wioletta Jarmużek, Jacek Rubik, Marek Migdał, Maciej Pronicki
Pediatric Transplantation.2015; 19(5): E115.     CrossRef
Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks
Hervé Ghesquières
Leukemia & Lymphoma.2015; 56(6): 1577.     CrossRef
Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis
Xuqin Jiang, Xiaodong Mei, Di Feng, Xiaojing Wang, Herbert B. Tanowitz
PLOS ONE.2015; 10(4): e0122171.     CrossRef
Consensus guidelines for diagnosis, prophylaxis and management ofPneumocystis jiroveciipneumonia in patients with haematological and solid malignancies, 2014
L. Cooley, C. Dendle, J. Wolf, B. W. Teh, S. C. Chen, C. Boutlis, K. A. Thursky
Internal Medicine Journal.2014; 44(12b): 1350.     CrossRef
Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy
Tark Kim, Sang-Ho Choi, Sung-Han Kim, Jin-Yong Jeong, Jun Hee Woo, Yang Soo Kim, Heungsup Sung, Mi-Na Kim, Dok Hyun Yoon, Cheolwon Suh, Sang-Oh Lee
Annals of Hematology.2013; 92(2): 231.     CrossRef
Non-infectious pulmonary toxicity of rituximab: a systematic review
A. V. Hadjinicolaou, M. K. Nisar, H. Parfrey, E. R. Chilvers, A. J. K. Ostor
Rheumatology.2012; 51(4): 653.     CrossRef
Pulmonary toxicities from targeted therapies: a review
Nicholas A. Barber, Apar Kishor Ganti
Targeted Oncology.2011; 6(4): 235.     CrossRef